MEHBOOB NAZARANI: Open Payments
NPI 1235148826 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$118 in 6 payments from 4 companies in 2025. Trend: 2023 $0 · 2024 $229 · 2025 $118
Food & beverage: $118
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| Alkermes, Inc. | 2 | $35 |
| Neurocrine BioSciences, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
Products named: CAPLYTA, ARISTADA, INGREZZA, REXULTI.
Industry payments across TX — which companies pay providers there.
